Press Releases

AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference

March 5, 2019 at 7:00 AM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2019-- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the Company will present at the Cowen and Company 39th Annual Health Care Conference onWednesday, March 13, 2019, at 8:40 a.m. ET at the Marriott Copley Place in Boston.

Geoff MacKay, AVROBIO’s President and Chief Executive Officer, will provide an overview of the Company and a business update. A live webcast of the presentation will also be available under "Events and Presentations" in the Investors section of the Company's website at www.avrobio.com. An archived webcast recording of the event will be available on the website for approximately 30 days.

About AVROBIO, Inc.

AVROBIO, Inc., is a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose. AVROBIO’s lentiviral-based gene therapies employ hematopoietic stem cells that are collected from the patient and then modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. AVROBIO is focused on the development of its gene therapy, AVR-RD-01, in Fabry disease, as well as additional investigational gene therapy programs including in Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform incorporates a vector system and an automated, closed, cell manufacturing solution designed to enable worldwide commercialization. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.

Source: AVROBIO, Inc.

Investors:
Christopher F. Brinzey
Westwicke Partners
339-970-2843
chris.brinzey@westwicke.com

Media:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com